UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 12b-25
SEC FILE NUMBER
 
000-55523
 
NOTIFICATION OF LATE FILING
CUSIP NUMBER
 
03815L102
 
(Check One):
o
Form 10-K
o
Form 20-F
o
Form 11-K
x
Form 10-Q
 
o
Form 10-D
o
Form N-SAR
o
Form N-CSR
 

 

 For Period Ended: December 31, 2019                                     

 

 

 

 

 o Transition Report on Form 10-K

 

 o Transition Report on Form 20-F

 

 o Transition Report on Form 11-K

 

 o Transition Report on Form 10-Q

 

 o Transition Report on Form N-SAR

 

 

 

 

 For the Transition Period Ended: ___________________
  
Read Instructions (on back page) Before Preparing Form. Please Print or Type.
 
NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION HAS VERIFIED ANY INFORMATION CONTAINED HEREIN.
 
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
 
PART I -- REGISTRANT INFORMATION
  

Full Name of Registrant:

Applied BioSciences Corp.

 

 

Former Name if Applicable:

None

 

 

Address of Principal Executive Offices (Street and Number):

9701 Wilshire Blvd., Suite 1000, Beverly Hills, California 90212.
 
 
 
 
 
 
PART II -- RULES 12b-25(b) AND (c)
 
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed (Check box if appropriate)
 
x
(a)
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
 
(b)
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
   
(c)
The accountant's statement or other exhibit required by Rule 12(b)-25(c) has been attached if applicable.
 
PART III -- NARRATIVE
 
State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.
 
The Registrant has been unable, without unreasonable effort or expense, to timely compile all information for the financial statements and related disclosures required to be included in its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2019. Registrant expects to file the Quarterly Report on or before February 19, 2020.
 
PART IV -- OTHER INFORMATION
 
(1) Name and telephone number of person to contact in regard to this notification:
  
Raymond W. Urbanski
 
(310)
 
356-7374
Name
 
Area Code
 
Telephone Number
 
(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). x Yes     o No

 

 
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof ? o Yes     x No
  
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
 
 
2
 
 
 
Applied BioSciences Corp.
(Name of Registrant as Specified in Charter)
 
has caused this notification to be signed on their behalf by the undersigned hereunto duly authorized.
 
Date: February 14, 2020
By:
/s/ Raymond W. Urbanski
Name:
Raymond W. Urbanski
 
Title:
Chief Executive Officer
 
  
Instruction: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the form.
 
ATTENTION
 
INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACT CONSTITUTE FEDERAL CRIMINAL VIOLATIONS (SEE 18 U.S.C. 1001).
 
 

3
 
Applied Biosciences (CE) (USOTC:APPB)
Historical Stock Chart
From Dec 2020 to Jan 2021 Click Here for more Applied Biosciences (CE) Charts.
Applied Biosciences (CE) (USOTC:APPB)
Historical Stock Chart
From Jan 2020 to Jan 2021 Click Here for more Applied Biosciences (CE) Charts.